147 related articles for article (PubMed ID: 10453279)
1. Vitamin D and prostate cancer: biologic interactions and clinical potentials.
Miller GJ
Cancer Metastasis Rev; 1998-1999; 17(4):353-60. PubMed ID: 10453279
[TBL] [Abstract][Full Text] [Related]
2. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D and prostate cancer.
Stewart LV; Weigel NL
Exp Biol Med (Maywood); 2004 Apr; 229(4):277-84. PubMed ID: 15044710
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
5. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and prostate cancer.
Konety BR; Getzenberg RH
Urol Clin North Am; 2002 Feb; 29(1):95-106, ix. PubMed ID: 12109360
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D in prostate cancer.
Trump DL; Aragon-Ching JB
Asian J Androl; 2018; 20(3):244-252. PubMed ID: 29667615
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D.
Nonn L; Peng L; Feldman D; Peehl DM
Cancer Res; 2006 Apr; 66(8):4516-24. PubMed ID: 16618780
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
Miller GJ; Stapleton GE; Hedlund TE; Moffat KA
Clin Cancer Res; 1995 Sep; 1(9):997-1003. PubMed ID: 9816072
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness of osteoblastic and osteolytic bone metastases to vitamin D analogs.
Peleg S
Crit Rev Eukaryot Gene Expr; 2007; 17(2):149-58. PubMed ID: 17725485
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D and prostate cancer.
Feldman D; Skowronski RJ; Peehl DM
Adv Exp Med Biol; 1995; 375():53-63. PubMed ID: 7645428
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
Stewart LV; Lyles B; Lin MF; Weigel NL
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):37-46. PubMed ID: 16076555
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
Oades GM; Dredge K; Kirby RS; Colston KW
BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
Peehl DM; Skowronski RJ; Leung GK; Wong ST; Stamey TA; Feldman D
Cancer Res; 1994 Feb; 54(3):805-10. PubMed ID: 7508338
[TBL] [Abstract][Full Text] [Related]
17. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion.
Hedlund TE; Moffatt KA; Uskokovic MR; Miller GJ
Clin Cancer Res; 1997 Aug; 3(8):1331-8. PubMed ID: 9815816
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
[TBL] [Abstract][Full Text] [Related]
19. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
Yee SW; Campbell MJ; Simons C
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
